Transcriptional Assessment of Striatal mRNAs as Valid Biomarkers of Disease Progression in Three Mouse Models of Huntington’s Disease
DOI: 10.3233/JHD-190389 Afshin Ghavami 1, Michael Olsen 1, Mei Kwan 1, Jose Beltran 1, John Shea 1, Sylvie Ramboz 1, Wenzhen Duan 2, Daniel Lavery 3, David Howland 3, Larry C Park 3 Abstract Background: Huntington’s disease (HD) is a progressive...
Taleen Hanania, Ph.D.
Dr. Hanania received her Ph.D. in pharmacology at the University of Texas Medical Branch, Galveston. She completed her postdoctoral training...
NeuroCube® In Vivo AI Platform for Neurological Phenotyping
NeuroCube® is designed to evaluate gait to assess the impact of treatments on motor impairment disorders and pain. It provides...
Validated Phenotypic Approach to Neuropsychiatric Drug Discovery
Leahy E Drug Development & Delivery March 2019 Vol 19 No 2: 46-49. At the recent American College of Neuropsychopharmacology...
Stephen Morairty, Ph.D.
Dr. Stephen Morairty has over 30 years of experience in research and drug development focusing on translational neuroscience and EEG...
Christina Leahy
Christina Leahy has more than 35 years of experience in the pharmaceutical and biotechnology industries, the last 20 years with...
Thank You
Thank you for your message. Our team will be back in touch with you shortly. If you would like to...
Preclinical Parkinson’s Disease Studies
Parkinson’s disease is a chronic degenerative neurological disorder affecting millions globally. Its manifestation — the death of dopaminergic cells in...